Insider Selling: Guardant Health (NASDAQ:GH) Director Sells $15,102.04 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $130.19, for a total transaction of $15,102.04. Following the sale, the director directly owned 8,796 shares of the company’s stock, valued at $1,145,151.24. The trade was a 1.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Monday, May 18th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $95.96, for a total transaction of $11,131.36.
• On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $84.83, for a total transaction of $9,840.28.
• On Wednesday, March 18th, Musa Tariq sold 348 shares of Guardant Health stock. The stock was sold at an average price of $88.09, for a total transaction of $30,655.32.

Guardant Health Trading Up 2.1%

GH opened at $131.78 on Friday. Guardant Health, Inc. has a twelve month low of $40.35 and a twelve month high of $135.00. The firm has a market capitalization of $17.47 billion, a PE ratio of -38.87 and a beta of 1.61. The firm’s 50-day moving average price is $106.46 and its 200 day moving average price is $102.68.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Barclays boosted their target price on Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Citigroup increased their price target on Guardant Health from $135.00 to $150.00 and gave the company a “buy” rating in a report on Friday, February 20th. Royal Bank Of Canada initiated coverage on Guardant Health in a research report on Thursday, June 11th. They set an “outperform” rating and a $185.00 price objective on the stock. Guggenheim lowered Guardant Health from a “buy” rating to a “buy” rating in a research note on Thursday, May 28th. Finally, Wells Fargo & Company upped their target price on Guardant Health from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, February 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $141.95.

Hedge Funds Weigh In On Guardant Health

Institutional investors and hedge funds have recently bought and sold shares of the company. V Square Quantitative Management LLC purchased a new stake in shares of Guardant Health during the 4th quarter valued at approximately $27,000. Chesapeake Asset Management LLC acquired a new position in Guardant Health in the fourth quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Guardant Health in the fourth quarter worth approximately $31,000. Elyxium Wealth LLC purchased a new position in Guardant Health in the fourth quarter worth approximately $35,000. Finally, Parallel Advisors LLC increased its stake in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after acquiring an additional 219 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.